Free Trial

ProQR Therapeutics (PRQR) News Today

$1.71
0.00 (0.00%)
(As of 06/21/2024 09:00 PM ET)
ProQR Therapeutics logo with Medical background
StockNews.com Lowers ProQR Therapeutics (NASDAQ:PRQR) to Sell
StockNews.com downgraded ProQR Therapeutics from a "hold" rating to a "sell" rating in a report on Friday.
ProQR Therapeutics logo with Medical background
ProQR Therapeutics (NASDAQ:PRQR) Raised to "Hold" at StockNews.com
StockNews.com upgraded ProQR Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday.
ProQR Therapeutics logo with Medical background
ProQR Therapeutics (NASDAQ:PRQR) Rating Lowered to Sell at StockNews.com
StockNews.com downgraded shares of ProQR Therapeutics from a "hold" rating to a "sell" rating in a report on Wednesday.
ProQR Therapeutics logo with Medical background
ProQR Therapeutics (NASDAQ:PRQR) Shares Pass Above 50 Day Moving Average of $2.02
ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Above 50-Day Moving Average of $2.02
ProQR Therapeutics (NASDAQ:PRQR) Cut to "Sell" at StockNews.com
StockNews.com downgraded shares of ProQR Therapeutics from a "hold" rating to a "sell" rating in a report on Friday.
ProQR Therapeutics' (PRQR) "Buy" Rating Reaffirmed at Chardan Capital
Chardan Capital reiterated a "buy" rating and issued a $2.50 target price on shares of ProQR Therapeutics in a report on Friday.
ProQR retains key patent for RNA editing technology
Citigroup Raises ProQR Therapeutics (NASDAQ:PRQR) Price Target to $2.00
Citigroup increased their target price on shares of ProQR Therapeutics from $1.80 to $2.00 and gave the company a "buy" rating in a research report on Thursday.
ProQR Therapeutics N.V. (PRQR)
ProQR Therapeutics (NASDAQ:PRQR) Given Consensus Recommendation of "Buy" by Analysts
ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) has been assigned a consensus rating of "Buy" from the five analysts that are covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have covered
ProQR Therapeutics (NASDAQ:PRQR) Given "Buy" Rating at HC Wainwright
HC Wainwright restated a "buy" rating and issued a $5.00 price objective on shares of ProQR Therapeutics in a report on Thursday.
Chardan Capital Boosts ProQR Therapeutics (NASDAQ:PRQR) Price Target to $2.50
Chardan Capital lifted their price objective on shares of ProQR Therapeutics from $2.00 to $2.50 and gave the company a "buy" rating in a research note on Thursday.
ProQR Therapeutics (NASDAQ:PRQR) Short Interest Update
ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) saw a large drop in short interest in February. As of February 29th, there was short interest totalling 263,900 shares, a drop of 17.3% from the February 14th total of 319,000 shares. Based on an average trading volume of 302,700 shares, the days-to-cover ratio is currently 0.9 days. Approximately 0.6% of the shares of the stock are short sold.
ProQR Therapeutics (NASDAQ:PRQR) Upgraded by StockNews.com to Buy
StockNews.com upgraded ProQR Therapeutics from a "hold" rating to a "buy" rating in a research report on Monday.
PRQR Mar 2024 2.500 call
ProQR Therapeutics N.V.
ProQR Therapeutics (NASDAQ:PRQR) Given Consensus Recommendation of "Buy" by Brokerages
ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) has been assigned an average recommendation of "Buy" from the five research firms that are presently covering the firm, Marketbeat reports. Five analysts have rated the stock with a buy recommendation. The average 12 month price target among analy
StockNews.com Downgrades ProQR Therapeutics (NASDAQ:PRQR) to Hold
StockNews.com lowered shares of ProQR Therapeutics from a "buy" rating to a "hold" rating in a report on Friday.
4 Biotech Stocks With Massive Buy Potential
StockNews.com Upgrades ProQR Therapeutics (NASDAQ:PRQR) to Buy
StockNews.com raised ProQR Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday.
ProQR Therapeutics (NASDAQ:PRQR) Sees Large Decrease in Short Interest
ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) was the target of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 680,400 shares, a decrease of 30.6% from the December 15th total of 981,100 shares. Based on an average trading volume of 204,200 shares, the short-interest ratio is currently 3.3 days. Currently, 1.4% of the company's shares are sold short.
ProQR Therapeutics (NASDAQ:PRQR) Stock Rating Upgraded by StockNews.com
StockNews.com raised ProQR Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday.
Get ProQR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter.

Trump conviction scandal exposed (Ad)

In this new documentary, you’ll discover the truth about Trump’s criminal conviction, who’s really pulling the puppet strings, and why this is just phase one in their dark plan to reshape America. It’s not just about blocking Trump’s re-election…

To get all the details, go here now.

PRQR Media Mentions By Week

PRQR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PRQR
News Sentiment

-0.30

0.69

Average
Medical
News Sentiment

PRQR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PRQR Articles
This Week

2

1

PRQR Articles
Average Week

Get ProQR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:PRQR) was last updated on 6/24/2024 by MarketBeat.com Staff

From Our Partners